Meeting slides
Interactive presentation

Immunopathogenesis of SLE

This short 3D animation reviews the immunopathogenesis of systemic lupus erythematosus (SLE), relevant disease pathophysiology, and newer targeted therapies.
Suggested Readings

European League Against Rheumatism (EULAR) 2020 Annual Meeting Abstracts.

June 3-6, 2020. Virtual.

American College of Rheumatology (ACR) Annual Meeting Abstracts.

November 5-9, 2020. Virtual.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

Furie RA, et al. Lancet Rheumatol. 2019;1(4):e208-e219.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.

Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.

Two-year, randomized, controlled trial of belimumab in lupus nephritis.

Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis.

Arriens C, et al. Ann Rheum Dis. 2020;79(suppl 1):172-173.

B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis.

Furie R, et al. Lupus Sci Med. 2020;7(suppl 1):A27-A28.

Comprehensive efficacy of anifrolumab across organ domains in patients with active SLE: pooled data from 2 phase 3 trials.

Morand E, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Flare reduction and oral corticosteroid taper in patients with active SLE treated with anifrolumab in 2 phase 3 trials.

Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis.

Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).